NRXSNeuraxis Inc. Common Stock
6.150USD-3.60%Mkt Cap: 77.23M $P/E: —3d ago
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous …
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin. | ||
 NeurAxis, Inc. Q2 2026 Earnings Call Summary Moby summary of NeurAxis, Inc.'s Q2 2026 earnings call | ||
Neuraxis Inc (NRXS) (Q2 2026) Earnings Call Highlights: Revenue Surges 116% as Payer Coverage ... Neuraxis Inc (NRXS) reports record Q2 growth with gross margins expanding to 85.9% while strategically investing in VA channel expansion and large payer negotiations. | ||